To receive daily emails from Breaking Christian News to your inbox CLICK HERE

"There just aren't very good treatments for low-grade ovarian cancer, so this discovery opens up a lot of new exciting possibilities for us." -Dr. John Farley

Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.

The findings, published in the Feb. 14 edition of The Lancet Oncology, show that selumetinib targets a mutation in the MAPK pathway for patients with low-grade serous carcinoma, allowing for treatment on previously chemoresistant tumors.

"This is a potentially important breakthrough for the Gynecologic Oncology Group," said John Farley, MD, a gynecologic oncologist in the Division of Gynecologic Oncology and the Department of Obstetrics and Gynecology at the Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, a Dignity Health Member.

This study was initially developed in 2007, with 52 patients enrolled for the Phase II clinical trial between December 2007 and November 2009. Patients were given 50 milligrams of selumetinib orally twice daily. Of those participants, eight had a measurable decrease in tumor size, seven had partial responses and 34 patients saw their tumors stabilize. The findings suggest that inhibitors of the MAPK pathway warrant further investigation in patients with low-grade ovarian cancer.

"There just aren't very good treatments for low-grade ovarian cancer, so this discovery opens up a lot of new exciting possibilities for us," Dr. Farley said. He added that Phase III of this trial is scheduled to begin in the next few weeks, with that trial to be the "definitive test" before the treatment becomes available to the general population.

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Veterans Day 2026: Here's Every Place Offering Freebies, Discounts to Our Vets

A Proclamation of Gratitude and Progress for America's Veterans

Ancient Evidence Suggests Roman Emperor Sought to Recognize Jesus as God

Charlie Kirk's Family 'Deeply' Disappointed by Tyler Robinson's Trial Delay

Texas Democrats Launch MASSIVE Assault on Second Amendment Just Days after Election Sweep

Gaza-Born DSAer Ahmed Moor Challenges Sen. John Fetterman in PA; Advises Hamas and Palestinian Islamic Jihad Charity, Praised the Oct. 7 Slaughter in Israel

President Trump Chooses Stephen Miller as White House Chief of Staff

SCOTUS: Border Wall Construction Can Resume, Saving Government a Half-Million Dollars a Day

Secretary Hegseth: Impeachment Charges a Stunt 'Driven by Ego and Resentment'

NBC Drops 'National Anthem' from Football Broadcast

Nvidia CEO Jensen Huang Apologizes as Firm Probes Affair with Alleged Chinese Spy

Prayer Alert: Hackers Target America's Freezers; A Threat to Food and Medicine

After the Midterms, What's Next? History Tells Us

'Missing' Memory Card Flips Georgia House Race for GOP

US Supreme Court Likely to Rule in Favor of Catholic Preschool in Religious Liberty Case, Experts Say

Gratitude Changes Your Brain. Here's How

Allie Beth Stuckey Launches a New Space for Christian Women and Moms

2 in 3 Churchgoers Fail Bible Literacy Quiz

This Hail Mary Move Could Save the Supreme Court from the Democrats

Another Florida WIN: CAIR-Florida Shutters Operations as Judge Leaves Terror Designation Intact

Steve Shultz, Managing Editor
Founder and Owner

Aimee Herd, Editor